Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors

Aim of this review article was to critically analyze the recently described cytogenetic and molecular markers for testicular germ cell tumors with regard to their clinical utility. The isochromosme i(12p) represents the most common and characteristic cytogenetic finding which already appears in testicular carcinoma in situ. A number of proto–oncogenes (cyclin D and PTHLH) as well as putative tumor suppressor genes are localized on 12p; however, their role in pathogenesis and prognosis of testicular germ cell tumors has not been defined yet. Clinical characteristics of patients with familial testicular germ cell tumors indicate a genetic background for the development of testicular tumors. Although a number of chromosomal loci encoding potential testicular tumor susceptibility genes have been identified, the genetic basis of testicular cancer pathogenesis is still unknown. With regard to molecular prognostic risk factors most of the reported data on proliferation markers, tumor suppressor genes, proteases and adhesion molecules have to be confirmed in prospective randomized trials prior to their widespread clinical use. Based on the available data on prospective studies the percentage of embryonal carcinoma and vascular invasion appear to be the most significant prognosticators. Investigation and identification of those factors determining the aggressive biologic behavior of embryonal carcinoma compared to all other histological components appear to be most promising in the research for prgnosticators of metastatic disease. In conclusion, the increasing knowledge of molecular genetic events involved in pathogenesis and prognosis of testicular germ cell tumors will not only help to better understand development and progression of testicular cancer, but it will also define new approaches to classification and management of germ cell tumors

[1]  T. Strohmeyer,et al.  Glutathione S-transferases in human testicular germ cell tumors: changes of expression and activity. , 1992, The Journal of urology.

[2]  T. Furuchi,et al.  Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl-2 in spermatogonia. , 1996, Development.

[3]  C. Chresta,et al.  Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.

[4]  A. Fraioli,et al.  Stone Recurrence after Lithotripsy in Patients with Recurrent Idiopathic Calcium Urolithiasis: Efficacy of Treatment with Fiuggi Water , 2000, European Urology.

[5]  T. Miki,et al.  Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors. , 1997, The Journal of urology.

[6]  R. Lothe,et al.  Molecular genetic changes in human male germ cell tumors. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[7]  G. Viglietto,et al.  Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. , 1996, Oncogene.

[8]  J. Moul,et al.  Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. , 1995, The Journal of urology.

[9]  G. Sledge,et al.  Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. , 1994, Cancer research.

[10]  R. Fimmers,et al.  MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. , 1998, Cancer.

[11]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[12]  I. Damjanov Pathogenesis of testicular germ cell tumours. , 1993, European urology.

[13]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Slamon,et al.  Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. , 1995, The Journal of urology.

[15]  R. Tarone,et al.  The measurement of cisplatin-DNA adduct levels in testicular cancer patients. , 1988, Carcinogenesis.

[16]  N. Skakkebaek,et al.  Possible carcinoma-in-situ of the testis. , 1972, Lancet.

[17]  B. Gallie,et al.  Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.

[18]  T. Strohmeyer,et al.  FAULTY CELL CYCLE RESTRICTION POINT G1/S IN HUMAN TESTICULAR TUMORS: DEREGULATION OF E2F-1, CYCLIN DEPENDENT KINASE 2 (CDK2) and CYCLIN D2 GENE EXPRESSION , 1999 .

[19]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[20]  E. Mumperow,et al.  Spermatic Cord β-Human Chorionic Gonadotropin Levels in Seminoma and their Clinical Implications , 1992 .

[21]  L. Looijenga,et al.  Interphase cytogenetics of carcinoma in situ of the testis. Numeric analysis of the chromosomes 1, 12 and 15. , 1993, European urology.

[22]  J. Moul,et al.  Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization , 1992, Genes, chromosomes & cancer.

[23]  J. Moul,et al.  Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1993, The Journal of urology.

[24]  L. Liotta,et al.  Molecular aspects of tumor cell invasion and metastasis , 1993, Cancer.

[25]  J. Moul,et al.  Prognostic factors in low-stage nonseminomatous testicular cancer. , 1996, Oncology.

[26]  C. Cordon-Cardo,et al.  Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Ulbright,et al.  Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis , 1995, Cancer.

[29]  J. Bartek,et al.  p53 Protein alterations in human testicular cancer including pre‐invasive intratubular germ‐cell neoplasia , 1991, International journal of cancer.

[30]  C. Catton,et al.  Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. , 1997, The Journal of urology.

[31]  Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. , 1996, The Journal of urology.

[32]  D. Bishop,et al.  Candidate regions for testicular cancer susceptibility genes , 1998, Human molecular genetics.

[33]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[34]  T. Strohmeyer,et al.  Alterations of the metastasis suppressor gene nm23 and the proto-oncogene c-myc in human testicular germ cell tumors. , 1997, The Journal of urology.

[35]  K. Dieckmann,et al.  Immunohistological determination of proliferative activity in seminomas. , 1988, Journal of Clinical Pathology.

[36]  F. Mostofi,et al.  Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis , 1998, Cancer.

[37]  E. Mariman,et al.  Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. , 1994, Journal of the National Cancer Institute.

[38]  J. Serth,et al.  Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis , 1996, Cancer.

[39]  I. Shaw Detection of the c-myc oncogene product in testicular cancer. , 1985, British Journal of Cancer.

[40]  S. Melmed,et al.  Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. , 1995, The Journal of urology.

[41]  T. Miki,et al.  Doppler Resistive Index in Benign Prostatic Hyperplasia: Correlation with Ultrasonic Appearance of the Prostate and Infravesical Obstruction , 2000, European Urology.

[42]  P. Goss,et al.  Loss of heterozygosity of tumor suppressor genes in testis cancer. , 1995, Cancer research.

[43]  P. Albers,et al.  Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors , 1994, Cancer.

[44]  J. Moul,et al.  Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[45]  J. Moul,et al.  Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. , 1998, The Journal of urology.

[46]  D. Slamon,et al.  Expression of p21 ras oncoproteins in human cancers. , 1986, Cancer research.

[47]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[48]  A. Heidenreich,et al.  Screening, Diagnostik und Therapie der testikulären intraepithelialen Neoplasie (TIN) , 1995 .

[49]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[50]  J. Stewart,et al.  The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. , 1986, British Journal of Cancer.

[51]  R. Chaganti,et al.  Cytogenetics of male germ-cell tumors. , 1993, The Urologic clinics of North America.

[52]  V. Reuter,et al.  Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Ullrich,et al.  Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. , 1991, Cancer research.

[54]  J. Moul,et al.  MOLECULAR ANALYSIS OF P16Ink4/CDKN2 AND P15Ink4B/MTS2 GENES IN PRIMARY HUMAN TESTICULAR GERM CELL TUMORS , 1998 .

[55]  Y. Nakamura,et al.  Loss of 3p or 11p alleles is associated with testicular cancer tumors. , 1989, Genomics.

[56]  F. Mostofi,et al.  Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. , 1997, The Journal of urology.

[57]  V. Reuter,et al.  Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction , 1990, Genes, chromosomes & cancer.

[58]  B. Tycko Genomic imprinting: mechanism and role in human pathology. , 1994, The American journal of pathology.

[59]  J. Oosterhuis,et al.  Cytogenetics of carcinoma in situ of the testis. , 1990, Cancer genetics and cytogenetics.

[60]  J. Moul,et al.  Prognostic risk factors in low stage testicular germ cell tumors , 1997, Cancer.

[61]  D. Forman,et al.  Candidate regions for a testicular cancer susceptibility gene , 1995 .

[62]  D. Slamon,et al.  Mutations of the p53 gene are not detectable in human testicular tumors. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[63]  H. Schmoll,et al.  Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular‐cancer cell lines differing in their sensitivity to standard agents , 1994, International journal of cancer.

[64]  A. de la Chapelle,et al.  Oncogenes in human testicular cancer: DNA and RNA studies. , 1991, British Journal of Cancer.

[65]  L. Martínez-Piñeiro,et al.  Determination of the Percentage of Free Prostate–Specific Antigen Helps to Avoid Unnecessary Biopsies in Men with Normal Rectal Examinations and Total Prostate–Specific Antigen of 4–10 ng/ml , 2000, European Urology.

[66]  Chunde Li,et al.  Chromosomal Numerical Aberrations Detected by Fluorescence in situ Hybridization on Bladder Washings from Patients with Bladder Cancer , 2000, European Urology.

[67]  Kazumi Suzuki,et al.  Serum Anti–p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients , 2000, European Urology.

[68]  P. Pollock,et al.  Compilation of somatic mutations of the CDKN2 gene in human cancers: Non‐random distribution of base substitutions , 1996, Genes, chromosomes & cancer.

[69]  F. Mostofi,et al.  Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1994, The Journal of urology.

[70]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[71]  W. Jiang,et al.  E‐cadherin and its associated protein catenins, cancer invasion and metastasis , 1996, The British journal of surgery.

[72]  K. Dieckmann,et al.  Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  E. Mumperow,et al.  Spermatic cord beta-human chorionic gonadotropin levels in seminoma and their clinical implications. , 1992, The Journal of urology.

[74]  M. Mandalà,et al.  Paradoxical Stimulation of Prolactin Secretion by L–Dopa in Metastatic Prostate Cancer and Its Possible Role in Prostate–Cancer–Related Hyperprolactinemia , 2000, European Urology.

[75]  N. Skakkebæk POSSIBLE CARCINOMA-IN-SITU OF THE TESTIS , 1972 .

[76]  M. Skolnick,et al.  CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.

[77]  H. Rochefort,et al.  Alterations and role of human cathepsin D in cancer metastasis. , 1996, Enzyme & protein.

[78]  J. Serth,et al.  Overexpression of the p53 oncoprotein in carcinoma in situ of the testis. , 1994, Pathology, research and practice.

[79]  J. Bos,et al.  Activated ras genes in human seminoma: evidence for tumor heterogeneity. , 1989, Oncogene.

[80]  D. Harrison,et al.  Natural disasters and man-made responses: are we protecting environmental health? , 1993, Environmental health perspectives.

[81]  A. Levine,et al.  A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation , 1996, Nature Medicine.

[82]  H. Walt,et al.  Isochromosome 12p in malignant testicular tumors. , 1985, Cancer genetics and cytogenetics.

[83]  T. Strohmeyer,et al.  Analysis of the DCC tumor suppressor gene in testicular germ cell tumors: mutations and loss of expression. , 1997, The Journal of urology.

[84]  R. Smith,et al.  Frequent loss of heterozygosity at 11p loci in testicular cancer. , 1995, The Journal of urology.

[85]  I. Bodrogi,et al.  Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins. , 1998, Anticancer research.

[86]  J W Moul,et al.  Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. , 1994, The Journal of urology.